ClinicalTrials.gg
CompletedNCT06398808Updated Dec 20, 2024

A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates

A Phase 2 interventional study of Arm1 and Arm 2 in Ulcerative Colitis, sponsored by Zydus Lifesciences Limited. Completed at 1 site in India. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-20.

Sponsored by Zydus Lifesciences Limited · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Colitis, Ulcerative with a site in India — 10 open to participants now, 20 under way, 8 of them phase 3. Colitis, Ulcerative · India.

Enrollment
55th of 56
24 · median 341
Started
2024
with 5 others
Phase 2
18 of 58
5 open now
Registered
42nd of 58
by date

Among the 58 studies in Colitis, Ulcerative with a site in India, this one is the 55th largest by enrollment of the 56 interventional ones that give a count, is one of 6 that started in 2024, is one of 18 in phase 2, and was the 42nd registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

10 of the 58 studies in Colitis, Ulcerative with a site in India are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Colitis, Ulcerative with a site in India, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy and safety of ZYIL1 oral capsule twice a day for 12 weeks for treatment of mild to moderate active ulcerative colitis resistant or intolerant to oral aminosalicylates.

Read the detailed description

This is a Phase IIa, randomized, two arms, double blind, double dummy, parallel, multicentre study to evaluate efficacy and safety of ZYIL1 oral capsules for the treatment of mild to moderately active ulcerative colitis resistant or intolerant to oral aminosalicylates.

The study consists

The study consists of: screening period of upto 4 weeks, treatment period of 12 weeks (first 6 weeks period: Induction period and remaining 6 weeks: Maintenance period), and end of the study at Week 13. The total duration of the study will be 119 days including screening period of 28 days.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients aged 18 to 75 years, both inclusive.
  2. Have had ulcerative colitis (UC) diagnosed at least 3 months prior to screening. The diagnosis of UC must be confirmed by endoscopic and histologic evidence.
  3. Mild to Moderate active disease defined as total score of at least 4 on the mMS, endoscopy subscore of at least 2 and a rectal bleeding sub-score of at least 1.
  4. Demonstrated an inadequate response to, loss of response to, or intolerance to any of the Oral aminosalicylates (e.g., mesalamine, sulfasalazine, olsalazine, balsalazide)

    ○ Signs and symptoms of persistently active disease, in the opinion of the investigator, during a current or prior course of at least 4 weeks of treatment with 2.4 g/day mesalamine, 4 g/day sulfasalazine, 1 g/day olsalazine, or 6.75 g/day balsalazide.

  5. Have undergone colonoscopy within the past 2 years for extent of disease, and if the UC has been present for > 10 years, have had a colonoscopy with to rule out dysplasia
  6. Patients who meet following laboratory values (assessed within 28 days prior to randomization):

    1. WBCs ≥2000/μL
    2. Neutrophils ≥1500/μL
    3. ≥100 X 10³/μL
    4. ≥8.5 g/dL
    5. Serum creatinine of ≤1.5 X or >40 mL/minute (using Cockcroft/Gault formula)
    6. \& ALT ≤1.5 X ULN
    7. Total ≤ 1.5 X ULN
  7. Men and women of must agree to use adequate measures during the study. Acceptable methods of birth control in this study include: surgical sterilization, intrauterine device, oral contraceptive, contraceptive patch, long acting injectable contraceptive, partner's vasectomy, double-barrier method (condom or diaphragm with spermicide) or abstinence for at least 4 weeks prior to study drug administration, during study participation and for 30 days after their last dose of study drug.
  8. All patients aged 45 years or over must have had a colonoscopy to screen for adenomatous polyps within 5 years of screening or must have had a colonoscopy at screening to assess for polyps.
  9. Ability to provide written and to be compliant with the schedule of protocol assessments. In case of illiterate patients, thumb impression of the patients will be obtained along with the signature of the impartial witness or legally authorized representative (LAR) on the consent form prior to patient's participation in the trial.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of Crohn's disease or indeterminate colitis or the presence or history of a fistula consistent with Crohn's disease.
  2. Have severe extensive colitis as evidenced by at least one of the following:

    1. Physician judgment that the patient is likely to require colectomy or ileostomy within 12 weeks of baseline.
    2. Current evidence of fulminant colitis, toxic megacolon or bowel perforation.
    3. Previous total colectomy
    4. Have 4 or more of the following i.e Body temperature > 38 C,HR > 110 (bpm),Focal severe or rebound abdominal tenderness,Anemia ( [Hgb] \< 8.5 g/dL), Transverse colon diameter > 5 cm on plain X-ray.
  3. Have positive stool culture for pathogens (O P, bacteria) or positive test for C.

    difficile at screening. If C. difficile is positive, the patient may be treated and retested.

  4. Patients who have an evidence of pathogenic bowel infection.
  5. History of recurrent or chronic infection (e.g. or C, syphilis, TB).
  6. Laboratory test positive for HBsAg, or at screening.
  7. Have had treatment with cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil (MMF) within 16 weeks of screening.
  8. History or planned concurrent treatment with biological agents (infliximab, adalimumab, vedolizumab, and ustekinumab), agents (e.g., azathioprine, 6-MP, or methotrexate) or with lymphocyte-depleting therapies (e.g., Campath, anti-CD4, cladribine, rituximab, ocrelizumab, cyclophosphamide, mitoxantrone, total body irradiation, bone marrow transplantation, alemtuzumab, daclizumab), Janus kinase (JAK) inhibitor (e.g.,Tofacitininb), (e.g., prednisolone) prior to randomization.
  9. History of treatment with an agent within 5 half-lives of that agent prior to randomization.
  10. History of treatment with topical rectal 5-ASA or steroids within 2 weeks of screening.
  11. Receipt of a within 4 weeks prior to randomization.
  12. Chronic use of therapies that strongly inhibit or induce metabolism within 4 weeks prior to randomization.
  13. cardiovascular, hepatic, neurological, pulmonary, ophthalmological, endocrine, psychiatric or other major systemic disease making implementation of the protocol or interpretation of the study difficult or that would put the patient at risk by participating in the study.
  14. Pregnant or lactating women or women of child bearing potential who have positive serum beta HCG test at screening.
  15. History of significant alcoholism or drug abuse within the past 1 year. History or presence of significant smoking (more than 10 cigarettes per day) or consumption of tobacco/nicotine products (more than 10 times per day).
  16. History of difficulty with donating blood
  17. Participants who have participated in any drug research study other than the present trial within past 3 months
  18. Patients that have undergone significant trauma or major surgery within 4 weeks of screening visit.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Arm 1 (ZYIL1 capsules & placebo)

    ZYIL1 capsules 25 mg for oral administration + 50 mg placebo

    Drug: Arm1

  • Active comparator
    Arm 2 (ZYIL1 capsules & placebo)

    ZYIL1 capsules 50 mg for oral administration + 25 mg placebo

    Drug: Arm 2

Interventions

06

What researchers measure

Primary outcomes

  1. To assess the efficacy of ZYIL1 for induction of clinical remission

    clinical remission defined as an mMS score of 0 to 2, including: stool frequency subscore 0 or 1, rectal bleeding subscore 0 and endoscopy score 0 or 1. mMS;modified Mayo Score Minimum value "0" and Maxium Value "9" Higher scores means worse outcome compare to baseline.

    Time frame: Baseline to week 6

Secondary outcomes

  1. Proportion of participants achieving clinical response

    Clinical Response defined decrease from baseline\* in the mMS of greater than or equal to 2 points mMS;modified Mayo Score Minimum value "0" and Maxium Value "9" Higher scores means worse outcome compare to baseline.

    Time frame: Week 6 and Week 12

  2. Proportion of participants in clinical remission

    clinical remission defined as an mMS score of 0 to 2, including: stool frequency subscore 0 or 1, rectal bleeding subscore 0 and endoscopy score 0 or 1. mMS;modified Mayo Score Minimum value "0" and Maxium Value "9" Higher scores means worse outcome compare to baseline.

    Time frame: Week 12

  3. Proportion of participants in endoscopic remission

    Time frame: Week 6 and Week 12

  4. Mean change in biomarker fecal calprotectin

    Time frame: Baseline to Week 6 & Week 12

07

Study locations

1 site
  • ICON Hospital
    Ahmedabad, Gujarat 380015, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Nov 2024, 7 months.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 7 months is below that.

Counting every sponsor, half of 155 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2024
First posted
May 3, 2024
StartActual
Apr 8, 2024
Primary completionActual
Nov 22, 2024
CompletionActual
Nov 28, 2024
Last update
Dec 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06398808
Responsible party
Sponsor
First posted
May 3, 2024
Start date
Apr 8, 2024
Primary completion
Nov 22, 2024
Completion
Nov 28, 2024
Last update
Dec 20, 2024

Study contacts

Dr. Deven Parmar, MD,FCP
study chair · Zydus Therapeutics Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Proteasomal Ubiquitin Receptor ADRM1

Start the discussion